树突状细胞融合瘤苗体内外诱导特异性抗白血病免疫的实验研究论文.docVIP

　　树突状细胞融合瘤苗体内外诱导特异性抗白血病免疫的实验研究论文 .freelia Immunity Induced by Dendritic Cells Fused or Cells Abstract This study ed to investigate the specific anti-L615 leukemia cell immunity induced by L615/DC fused cell vaccine in vivo and in vitro. BM-derived DCs bone marroice by culturing for 9-10 days in culture medium supplemented or cells fused cell vaccine，ice munized.After immunization，the specific proliferation ability and cytotoxicity against L615 leukemia cells in vitro ined by MTT and LDH methods.Anti-leukemia effect of fused cell vaccine in vivo munotherapy effects on L615 tumor-bearing mice.The results shoature and functional bone marro immunized mice e antigen at the second time，and could also elicit the effective cytotoxic activity against L615 leukemia cells in vitro， other groups.In vivo the average survival time of the tumor-bearing mice received immunotherapy or-bearing mice survived for long time，but the mice of control group died all，their average of survival time munized mice survived onths later.It is concluded that L615/ DC fused cell vaccine can improve the immunogenecity of L615 and induce effectively the specific anti-leukemia immunity against L615 leukemia cells to eliminate the residual leukemia cells，prolong the survival time and induce the immune memory to avoid the relapse.Thus，the fused cell vaccine may be an attractive strategy for malignance immunotherapy. Key or vaccine; acute leukemia; antitumor immunity 肿瘤细胞存在严重的抗原呈递障碍，但提高其表面MHC类分子和多种协同刺激分子的表达，可促进肿瘤抗原信号的传递。融合瘤苗是一种具有较高临床应用价值的肿瘤疫苗，通过将肿瘤细胞与专职抗原呈递细胞进行融合，形成的融合细胞同时表达肿瘤抗原肽-MHC复合物和多种协同刺激分子，可诱导出有效的特异性抗瘤免疫。与转基因技术相比，细胞融合的实验方法简便易行，且由于是多基因转移，可避免因单基因转移引起的肿瘤缺陷株或变异株的免疫逃逸现象。 成熟的树突状细胞（DC）表面表达大量的MHC-肽复合物［1］和多种协同刺激分子［2］，并分泌调节性细胞因子IL-12［3］，是功能最强的抗原呈递细胞。近年来由于DC制备方法的迅速发展和逐渐成熟，使获得大量符合实验需要的成熟DC成为可能，因此肿瘤细胞和DC的融合瘤苗成为杂交瘤技术在肿瘤研究领域中的又一个新突破。 迄今为止，细胞融合瘤苗的实验模型局限于实体瘤范围，对于血液系统恶性肿瘤的研究未见相关报道。本实验即以病毒诱发的纯系615小鼠急性T细胞白血病 L615细胞为肿瘤模型，利用骨髓来源的DC与照射灭活的L615细胞进行融合制备出L615/DC融合瘤苗，通过检测融合瘤苗在体内外诱导特异性抗白血病T细胞免疫反应的能力，来探讨融合瘤苗作为一种新型的白血病免疫治疗